Drug Repurposing of Cyclin-Dependent Kinase Inhibitors for Neutrophilic Acute Respiratory Distress Syndrome and Psoriasis

The document explores the potential of repurposing cyclin-dependent kinase (CDK) inhibitors, originally used in cancer treatment, for managing neutrophilic acute respiratory distress syndrome (ARDS) and psoriasis. CDK inhibitors, such as R-roscovitine, flavopiridol, and AT7519, target CDKs to regulate inflammatory responses in neutrophils, including inhibiting NETs formation and promoting neutrophil apoptosis, which helps resolve inflammation. CDK4/6 inhibitors like palbociclib and ribociclib show promise in reducing inflammation in these conditions. While preclinical evidence is promising, further clinical trials are needed to confirm their efficacy and safety, as well as address potential off-target effects and dose optimization challenges.